Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ACE Inhibitors Not Needed for Many Heart Disease Patients

09.11.2004


Many heart disease patients who are already receiving state-of-the-art therapy do not benefit from additional treatment with angiotensin converting enzyme (ACE) inhibitors, according to results of a new study funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. The study provides the most definitive evidence to date of the effect of the drug in stable heart disease patients whose heart function was shown to be at normal or near-normal levels, and whose heart disease was already well managed. Researchers found that ACE inhibitors do not lower the risk of cardiovascular death, heart attack, or the need for coronary revascularization (bypass surgery or angioplasty to restore blood flow to clogged arteries) in these patients.



Results of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) are being presented November 7 at the American Heart Association Scientific Sessions in New Orleans. They will also be published online concurrently by the New England Journal of Medicine and in the journal’s November 11 printed issue.* An editorial accompanies the article.

The American Heart Association currently recommends ACE inhibitors for all patients who have had a heart attack and others with coronary or other vascular disease. ACE inhibitors are a type of drug called vasodilators, meaning they cause blood vessel walls to widen or relax, thereby lowering blood pressure; they are one of several classes of drugs that are recommended for treating high blood pressure. Clinical studies have also found that ACE inhibitors improve survival and reduce the risk of heart attack among patients with heart failure, a condition in which the heart muscle is no longer pumping enough blood throughout the body. In addition, the drug has been shown to help prevent heart failure in some patients with moderate to severe ventricular dysfunction, or abnormalities in the lower chambers of the heart.


“Although ACE inhibitors have been proven to help patients with heart failure, until now it wasn’t clear whether all patients with coronary heart disease benefit from this class of drugs,” said NHLBI Acting Director Barbara Alving, M.D. “These results could significantly change clinical care of perhaps millions of Americans with heart disease.”

“This study indicates that many patients with coronary heart disease whose heart muscle is in good shape and who receive intense treatment including revascularization and lipid-lowering drugs do not gain extra cardiovascular protection from ACE inhibitors,” added Eugene Braunwald, M.D., who co-chaired the study with colleague Marc Pfeffer, M.D. Both are in the Cardiovascular Division of Brigham and Women’s Hospital in Boston.

“These lower-risk patients can avoid side effects and the added expense of ACE inhibitors without putting themselves at additional risk for cardiovascular complications,” Dr. Braunwald said. The drug’s side effects include cough, fainting spells, and a rare but serious allergic reaction known as angioedema.

Heart disease is the single leading cause of death in the United States. More than 13 million adults have coronary heart disease, putting them at increased risk for heart attack, sudden death, angina, heart failure, and stroke. Most patients with coronary heart disease, including heart attack survivors, however, do not have heart failure or ventricular dysfunction. PEACE was designed to test whether ACE inhibitors provide added benefits to this group of heart disease patients with relatively good heart function.

The PEACE trial involved nearly 8300 participants who did not have heart failure, and who had normal or near normal left ventricular function, as evidenced by left ventricular ejection fraction of greater than 40 percent. (The ejection fraction is an indication of the amount of blood that is pumped out of a filled ventricle; a normal rate is 50 percent or more.) The average age of participants when they started the trial was 64 years. The study was conducted at 180 clinical sites in the United States, Canada, Puerto Rico, and Italy.

All of the participants followed recommended treatments for heart disease as warranted. For example, 70 percent were on lipid-lowering medications (drugs to lower the level of LDL or “bad” cholesterol in the blood) and 72 percent had previously had coronary revascularization when they enrolled in the trial. Participants were then randomized to either take the standard dosage (4 mg/day) of the ACE inhibitor trandolapril (Mavik), or an inactive placebo. The drug was provided by Abbott Labs/Knoll.

After an average follow-up of 4.8 years, the same proportion (about 22 percent) of participants in each group died from cardiovascular disease (CVD), had a heart attack, or needed revascularization. The results did not differ when the researchers adjusted for the participants’ age, gender, or history of heart attack, transient ischemic attack, diabetes, or high blood cholesterol. Similarly, there were no differences based on which heart disease therapies participants followed during the study. Although trandolapril lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4.4 mm Hg, the reduction did not have a significant effect on the patients’ outcomes.

“PEACE tells us that patients with coronary disease and normal or only mildly reduced heart function do not benefit from ACE inhibitors unless the drug is being used to treat another condition, such as high blood pressure,” noted Michael Domanski, M.D., head of the NHLBI Clinical Trials Scientific Research Group, and a project officer of the study. “The entry criteria in PEACE can be used to help physicians decide which patients do not need ACE inhibitors.”

PEACE was the final in a series of three large clinical trials worldwide to test whether ACE inhibitors benefit heart disease patients who do not have heart failure. The participants in the PEACE trial were at lower risk both at baseline and after treatment compared to participants in the two earlier studies. Furthermore, although all three trials enrolled only patients who had no known heart failure or ventricular dysfunction, only PEACE used an ejection fraction found to be normal or slightly below normal using standard imaging tests as a key criterion for enrollment. The two earlier trials did not document the participants’ ejection fractions; thus, these participants could have had moderate to severe ventricular dysfunction.

“While the results from the PEACE study demonstrate that many patients with heart disease who are already receiving state-of-the-art therapy may not also need ACE inhibitors, it is important to remember that these drugs continue to be recommended for patients with heart failure or ventricular dysfunction,” said Yves Rosenberg, M.D. of NHLBI. Dr. Rosenberg is co-project officer of PEACE.

Approximately 5 million Americans have heart failure. Common causes of heart failure include coronary heart disease and high blood pressure. Based on the NHLBI’s Framingham Heart Study, approximately 22 percent of men and 46 percent of women who survive a heart attack will be disabled by heart failure within six years.

* The PEACE Trial Investigators. Angiotensin-converting–enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.

NHLBI Communications Office | EurekAlert!
Further information:
http://www.nhlbi.nih.gov
http://www.bsc.gwu.edu/peace

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>